Marks’ exit is not exactly helping industry sentiment

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. This weekend, I’ll be at the American Academy of Neurology meeting in San Diego. If you’ll also be there, come to our STAT event on Sunday night! I’ll be talking with researchers about the potential of using GLP-1 drugs for neurological conditions, and my Readout co-writer Meghana will be chatting with BMS’ head of development about the launch of their new schizophrenia drug Cobenfy. Register here.

Read the rest…